CMM has a winner for the Academy of Medical Sciences Poster and Presentation Competition
10 May 2017
The School of Cellular and Molecular Medicine congratulates Dr Madhu Kollareddy, who won the non-clinical prize, for the Academy of Medical Sciences Poster and Presentation
The Academy of Medical Sciences Poster and Presentation Prize competition, for the South West, was held on Friday 5 May 2017. The competition was open to all early career researchers (PhD students, postdoctoral and clinical fellows) working on biomedical topics in the South West of England (Cornwall, Devon, Dorset, Wiltshire, Somerset & Gloucestershire, plus unitary authorities and cities, i.e. Bristol, Exeter, Bath, Plymouth).
The competition had received over fifty poster entries from across the South West and they were reviewed by a panel of Academy of Medical Sciences fellows. Only the best four posters (two clinical and two non-clinical) were selected, with the entrants invited to present their work as a twenty-minute presentation, held at and event at the University of Bristol.
We were delighted to learn that two of the entrants were from the School of Cellular and Molecular Medicine, both in the non-clinical category, Dr Alex Greenhough and Dr Madhu Kollareddy.
Congratulations go to Dr Madhu Kollareddy who won a £250 cheque for the non-clinical prize, with Dr Alex Greenhough as a close second.
Madhu said of his win, "I felt overjoyed as soon as I learned that my work had been recognised as the best. This prize gave me a lot of confidence in the work I am doing and certainly helps my development towards an independent career. I felt very proud of my achievement, especially because my research represents the hard work of fundraisers at 'Neuroblastoma UK' and 'Smile with Siddy', without which I would not have had the opportunity to conduct this research."
Here are some details about Dr Madhu Kollareddy's work:
Dr Kollareddy's research looks into the development of new effective treatments for neuroblastoma. Approximately 50% of neuroblastoma are clinically high-risk with very poor survival rates. Within this subset of neuroblastoma patients, chemo-resistance and relapse is common. In search of effective treatments for a wide range of neuroblastomas, we recently discovered a novel small molecule inhibitor with anticancer activity. The new compound was cytotoxic on the majority of neuroblastoma cell lines, which are derived from high-risk group patients. The drug inhibited mitosis and subsequently induced apoptotic cell death by interfering with faithful division of cancer cells. Moreover, it was able to overcome chemo-resistance in several neuroblastoma cell line models and showed synergistic activity with other clinically used mitotic inhibitors. Such combination therapies should be useful for prevention of chemo-resistance, and therefore relapsing disease. In summary, his studies highlight the efficacy and mechanism of the action of a new therapy for neuroblastoma, and possibly other cancers.